FDA denies 3rd @Allergan petition challenging generic Restasis. @US_FDA says petition repeats many assertions from first two. Allergan’s patent transfer to tribe and ED Tex patent ruling received more attention, but with petition denial, there may be hope for generic entry.
— Michael Carrier (@profmikecarrier) January 5, 2018
